Combined Action of Two Synthetic Ultrashort Antimicrobial Peptides Exhibiting Synergistic Effects Against Clinically Significant Resistant Bacteria

Overview

Journal Vet World

Date 2025 Feb 3

PMID 39897351

Authors

Ali H Salama

Affiliations

Soon will be listed here.

Abstract

Background And Aim: The emergence and proliferation of multidrug-resistant bacteria pose a global health crisis. This issue arises from the overuse and misuse of antibiotics, coupled with the pharmaceutical industry's limited development of new drugs, which is constrained by financial disincentives and regulatory hurdles. This study aimed to investigate the combined antibacterial efficacy and safety profile of the combined ultrashort antimicrobial peptides (AMPs) WW-185 and WOW against antibiotic-resistant bacterial strains.

Materials And Methods: The WW-185 and WOW peptides were synthesized through solid-phase methods and purified using reverse-phase high-performance liquid chromatography, and their purity was confirmed by mass spectrometry. Antibacterial activity was evaluated using broth dilution and checkerboard assays to assess both individual and combined effects of the peptides against (including methicillin-resistant [MRSA]) and (including extended-spectrum beta-lactamases [ESBL]-producing strains). The synergy between the peptides was quantified using fractional inhibitory concentration indices. Hemolytic activity was also assessed to determine cytotoxicity toward red blood cells.

Results: The combination of WW-185 and WOW exerted synergistic effects against both MRSA and ESBL-producing , with reduced minimal inhibitory concentrations compared with the individual treatments. The peptides exhibited minimal hemolytic activity, indicating low toxicity.

Conclusion: The combination of the ultrashort AMPs WW-185 and WOW shows promising synergistic antibacterial effects against resistant bacteria, with potential for further therapeutic development due to their enhanced efficacy and low toxicity.

References

El Shazely B, Yu G, Johnston P, Rolff J . Resistance Evolution Against Antimicrobial Peptides in Alters Pharmacodynamics Beyond the MIC. Front Microbiol. 2020; 11:103. PMC: 7033599. DOI: 10.3389/fmicb.2020.00103. View

Serra-Burriel M, Keys M, Campillo-Artero C, Agodi A, Barchitta M, Gikas A . Impact of multi-drug resistant bacteria on economic and clinical outcomes of healthcare-associated infections in adults: Systematic review and meta-analysis. PLoS One. 2020; 15(1):e0227139. PMC: 6953842. DOI: 10.1371/journal.pone.0227139. View

Buda De Cesare G, Cristy S, Garsin D, Lorenz M . Antimicrobial Peptides: a New Frontier in Antifungal Therapy. mBio. 2020; 11(6). PMC: 7642678. DOI: 10.1128/mBio.02123-20. View

dEnfert C, Kaune A, Alaban L, Chakraborty S, Cole N, Delavy M . The impact of the Fungus-Host-Microbiota interplay upon Candida albicans infections: current knowledge and new perspectives. FEMS Microbiol Rev. 2020; 45(3). PMC: 8100220. DOI: 10.1093/femsre/fuaa060. View

Greco I, Molchanova N, Holmedal E, Jenssen H, Hummel B, Watts J . Correlation between hemolytic activity, cytotoxicity and systemic in vivo toxicity of synthetic antimicrobial peptides. Sci Rep. 2020; 10(1):13206. PMC: 7414031. DOI: 10.1038/s41598-020-69995-9. View

Thaker H, Cankaya A, Scott R, Tew G . Role of Amphiphilicity in the Design of Synthetic Mimics of Antimicrobial Peptides with Gram-negative Activity. ACS Med Chem Lett. 2013; 4(5):481-485. PMC: 3694626. DOI: 10.1021/ml300307b. View

Sun C, Zhao X, Jiao Z, Peng J, Zhou L, Yang L . The Antimicrobial Peptide AMP-17 Derived from Inhibits Biofilm Formation and Eradicates Mature Biofilm in . Antibiotics (Basel). 2022; 11(11). PMC: 9686669. DOI: 10.3390/antibiotics11111474. View

Salama A, Almaaytah A, Darwish R . The Design of Alapropoginine, a Novel Conjugated Ultrashort Antimicrobial Peptide with Potent Synergistic Antimicrobial Activity in Combination with Conventional Antibiotics. Antibiotics (Basel). 2021; 10(6). PMC: 8231522. DOI: 10.3390/antibiotics10060712. View

Mangoni M, Shai Y . Temporins and their synergism against Gram-negative bacteria and in lipopolysaccharide detoxification. Biochim Biophys Acta. 2009; 1788(8):1610-9. DOI: 10.1016/j.bbamem.2009.04.021. View

10.

Darwish R, Salama A . Study the Effect of Conjugate Novel Ultra-Short Antimicrobial Peptide with Silver Nanoparticles against Methicillin Resistant and ESBL . Antibiotics (Basel). 2022; 11(8). PMC: 9405122. DOI: 10.3390/antibiotics11081024. View

11.

Zasloff M . Antimicrobial peptides of multicellular organisms. Nature. 2002; 415(6870):389-95. DOI: 10.1038/415389a. View

12.

Huan Y, Kong Q, Mou H, Yi H . Antimicrobial Peptides: Classification, Design, Application and Research Progress in Multiple Fields. Front Microbiol. 2020; 11:582779. PMC: 7596191. DOI: 10.3389/fmicb.2020.582779. View

13.

Costa F, Carvalho I, Montelaro R, Gomes P, Martins M . Covalent immobilization of antimicrobial peptides (AMPs) onto biomaterial surfaces. Acta Biomater. 2010; 7(4):1431-40. DOI: 10.1016/j.actbio.2010.11.005. View

14.

Ma H, Zhao X, Yang L, Su P, Fu P, Peng J . Antimicrobial Peptide AMP-17 Affects by Disrupting Its Cell Wall and Cell Membrane Integrity. Infect Drug Resist. 2020; 13:2509-2520. PMC: 7398874. DOI: 10.2147/IDR.S250278. View

15.

Haney E, Mansour S, Hancock R . Antimicrobial Peptides: An Introduction. Methods Mol Biol. 2016; 1548:3-22. DOI: 10.1007/978-1-4939-6737-7_1. View

16.

Huang Y, Huang J, Chen Y . Alpha-helical cationic antimicrobial peptides: relationships of structure and function. Protein Cell. 2011; 1(2):143-52. PMC: 4875170. DOI: 10.1007/s13238-010-0004-3. View

17.

Zhang Q, Yan Z, Meng Y, Hong X, Shao G, Ma J . Antimicrobial peptides: mechanism of action, activity and clinical potential. Mil Med Res. 2021; 8(1):48. PMC: 8425997. DOI: 10.1186/s40779-021-00343-2. View

18.

Terreni M, Taccani M, Pregnolato M . New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives. Molecules. 2021; 26(9). PMC: 8125338. DOI: 10.3390/molecules26092671. View

19.

Hancock R, Sahl H . Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol. 2006; 24(12):1551-7. DOI: 10.1038/nbt1267. View

20.

Mahlapuu M, Hakansson J, Ringstad L, Bjorn C . Antimicrobial Peptides: An Emerging Category of Therapeutic Agents. Front Cell Infect Microbiol. 2017; 6:194. PMC: 5186781. DOI: 10.3389/fcimb.2016.00194. View